Pieris Pharmaceuticals, Inc.

Superior Medicines Through Efficient Biology

We combine leading protein engineering capabilities and deep insights into molecular drivers of disease to develop medicines that drive local biology to produce superior clinical outcomes.

Our Anticalin® Platform

Our Pursuit of Efficient Biology in Two Areas

Novel Solutions in Respiratory & Immuno-Oncology

Our pipeline is focused on inhalable Anticalin proteins to treat respiratory diseases locally and immuno-oncology multi-specifics tailored for the tumor microenvironment.

Browse Our Pipeline

We Are Biology-driven, Patient-focused

Actively Enrolling Patients in Clinical Trials

In our quest to provide solutions for patients, we are currently enrolling for our respiratory and immuno-oncology clinical trials.

View Our Patient Resources

Latest News

Latest News

Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021

View Press Release
Latest News

Pieris Pharmaceuticals Announces Inhaled CTGF Inhibitor PRS-220 for Idiopathic Pulmonary Fibrosis and 17 Million Dollar Grant From Bavarian Government To Accelerate Program Development for Post-COVID-19 Pulmonary Fibrosis

View Press Release
Latest News

Pieris Pharmaceuticals Receives Orphan Drug Designation for Cinrebafusp Alfa for the Treatment of Gastric Cancer

View Press Release
View All News

Join us in our mission to develop life-changing therapies!

Our passion and enthusiasm for science seek to transform the lives of patients. Learn more about how you can join our exceptional team!

Browse Career Opportunities